Speculative M&A Transaction Analysis, page-99

Hello, my friends.

Here is my second video discussing some of the science of Race Oncology and Bisantrene in comparison to other M&A peers. This is a follow on from my original post trying to determine a baseline value based on my own thoughts about what is and is not valuable or important to a pharmaceutical buyout. Within the presentation I cover clinical maturity, cancer indications, potential anti-cancer therapy synergies, first-in-class vs best-in-class, and pipeline potential of non-FDA approved and an FDA approved drug in comparison to Bisantrene.

Disclosures:
This is highly speculative and is not intended as financial advice. I state that you should do your own research before making your investment decision. The methodolgy I have used to determine the value of Bisantrene may be wrong. I reserve the right to change my thoughts on the matter if/when new data comes to light. I have included all the references for my work on the YouTube video. I am an independent investor and am not paid by RAC to do this work.

Happy to discuss any of this video in detail. I hope you enjoy.